The model predicted that compared to classic TKI plus capecitabine, a novel combination of TKI plus ADC was more effective in inducing tumor regression even at significantly lower doses, and it also suggested that sequential administration of HER2-ADC followed by TKI plus capecitabine would prolong response duration compared to direct TKI plus capecitabine alone, and both findings were validated by in vivo data. This evidence concerns the gene ERBB2 and neoplasm.